110 related articles for article (PubMed ID: 15912960)
1. Cathepsin S inhibitors as novel immunomodulators.
Thurmond RL; Sun S; Karlsson L; Edwards JP
Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
[TBL] [Abstract][Full Text] [Related]
2. Identification of a potent and selective noncovalent cathepsin S inhibitor.
Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
[TBL] [Abstract][Full Text] [Related]
3. Advances in cathepsin S inhibitor design.
Link JO; Zipfel S
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
[TBL] [Abstract][Full Text] [Related]
4. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin L maturation and activity is impaired in macrophages harboring M. avium and M. tuberculosis.
Nepal RM; Mampe S; Shaffer B; Erickson AH; Bryant P
Int Immunol; 2006 Jun; 18(6):931-9. PubMed ID: 16636015
[TBL] [Abstract][Full Text] [Related]
6. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
[TBL] [Abstract][Full Text] [Related]
7. Cross-presentation: underlying mechanisms and role in immune surveillance.
Rock KL; Shen L
Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
[TBL] [Abstract][Full Text] [Related]
8. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
Gupta S; Singh RK; Dastidar S; Ray A
Expert Opin Ther Targets; 2008 Mar; 12(3):291-9. PubMed ID: 18269339
[TBL] [Abstract][Full Text] [Related]
9. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
[TBL] [Abstract][Full Text] [Related]
10. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing.
Moss CX; Villadangos JA; Watts C
Eur J Immunol; 2005 Dec; 35(12):3442-51. PubMed ID: 16259009
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
Stoeckle C; Sommandas V; Adamopoulou E; Belisle K; Schiekofer S; Melms A; Weber E; Driessen C; Boehm BO; Tolosa E; Burster T
Cell Immunol; 2009; 255(1-2):41-5. PubMed ID: 19036358
[TBL] [Abstract][Full Text] [Related]
12. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
14. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins.
Reich M; van Swieten PF; Sommandas V; Kraus M; Fischer R; Weber E; Kalbacher H; Overkleeft HS; Driessen C
J Leukoc Biol; 2007 Apr; 81(4):990-1001. PubMed ID: 17261546
[TBL] [Abstract][Full Text] [Related]
15. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin cysteine proteases in cardiovascular disease.
Lutgens SP; Cleutjens KB; Daemen MJ; Heeneman S
FASEB J; 2007 Oct; 21(12):3029-41. PubMed ID: 17522380
[TBL] [Abstract][Full Text] [Related]
17. In vivo control of endosomal architecture by class II-associated invariant chain and cathepsin S.
Boes M; van der Wel N; Peperzak V; Kim YM; Peters PJ; Ploegh H
Eur J Immunol; 2005 Sep; 35(9):2552-62. PubMed ID: 16094690
[TBL] [Abstract][Full Text] [Related]
18. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security.
Gelin C; Sloma I; Charron D; Mooney N
J Leukoc Biol; 2009 Feb; 85(2):215-24. PubMed ID: 18809734
[TBL] [Abstract][Full Text] [Related]
19. Cysteine protease cathepsin S as a key step in antigen presentation.
Liu W; Spero DM
Drug News Perspect; 2004; 17(6):357-63. PubMed ID: 15334187
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the design of cathepsin S inhibitors.
Wiener JJ; Sun S; Thurmond RL
Curr Top Med Chem; 2010; 10(7):717-32. PubMed ID: 20337580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
